seeded either on plastic or bone slices prior to irradiation to investigate their numbers and function. Osteoblasts (OB) were differentiated from mouse calvariae, irradiated and analysed regarding their differentiation and function using alizarin red stain and qPCR. Hind legs of hTNFa tg mice were locally irradiated with 0.5 Gy of X-rays and consecutively analysed using histomorphological methods and mCT. Results Treatment of OC with LD-RT (0.5-2 Gy) lead to decreased differentiation and function, while OB showed increased mineralization after irradiation with 0.5 Gy. Further, no significant increase of Acp5 and catk at 0.5 Gy was found in OC while OB showed a dose-dependent decrease in RANK-L and increase in OPG expression. Also, OPG secretion by OB was enhanced at 0.5 Gy and 1 Gy. Histomorphometric analyses showed a decrease of erosive areas and OC numbers in the paws of irradiated animals, a finding that was confirmed in mCT images. Conclusions We conclude that LD-RT is not only a valuable tool for reduction of inflammation, but also has beneficial effects in restoring a balanced bone homeostasis through increased OB mineralization and decreased OC function. In the future, placebo controlled studies are desirable in order to investigate the effects of LD-RT with focus on osteoimmunology in RA in the clinic. Introduction Despite enormous efforts to develop new therapeutic strategies for treatment of rheumatoid arthritis (RA), the large number of non responding patients to currently available drugs underlies the unmet need to identify new therapeutic targets. Certain CD4 + T cells have been shown to be major drivers of inflammation in patients with RA. The expression of their key transcription factors is controlled by histone modifications which includes acetylation of lysine residues mediated by histone deacetylases (HDAC). Indeed, pan HDAC inhibitors have been shown to be a potential therapeutic strategy in the treatment of malignancies. However, major side effects limited the clinical use and underline the need of more specific HDAC inhibitors. Recent data suggest a role of HDAC1 on the migratory capacity and the differentiation of CD4 + T cells in the context of autoimmune encephalitis. Objectives Our aim was to elucidate the individual role of HDAC1 in a T cell dependent arthritis model, namely the collagen-induced arthritis model (CIA). Methods Mice with a T cell specific deletion of HDAC1 (HDAC1 cKO) were generated by using the CD4Cre/LoxP system. At week 8 of age arthritis was induced in wild type (WT) and HDAC1 cKO mice by immunising with chicken collagen II (CII), emulsified in complete Freund´s adjuvant. The animals were scored for clinical signs of arthritis, namely paw swelling and grip strength. Anti-CII antibody levels were determined by ELISA. Various cell subsets, including Th cells, where detected in the blood, the spleen and the draining lymph node by FACS analysis. To test antigen-specific T cell activation we performed in vitro restimulation of spleen and lymph node cells with collagen II followed by assessment of cytokine production and quantification of the proliferation rate using 3 H-thymidine incorporation. After 10 weeks mice were sacrificed and paraffin sections of the affected joints were analysed for histomorphologic signs of inflammation, cartilage and bone destruction. Results Eighty percent of the animals developed serum anti-CII anibodies (IgM and IgG). No difference in the production of antibody subclasses, especially of pathogenic IgG2c antibodies, were observed between WT and HDAC1 cKO mice. Surprisingly, HDAC1 cKO mice were completely protected and did not develop any clinical signs of arthritis. Accordingly, histological analysis revealed no signs of inflammation, no bone erosion and no appearance of osteoclasts in the joints of HDAC1 cKO mice. In line with our recently published data on the role of HDAC1 on the differentiation and migration of T cell subsets we suggest that HDAC1 plays a key role in the development of arthritis. Conclusions Our data show the importance of HDAC1 as a key immune regulator in the pathogenesis of T cell driven collagen induced arthritis. Therefore it might be considered as an interesting novel therapeutic target in RA. 
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1 However the effect of the different JAKi on activated fibroblast-like synoviocytes from patients with RA (RA-FLS) is not well characterised. Objectives This study compared the effect of different JAKi on the pro-inflammatory response of activated RA-FLS. Methods RA-FLS were isolated from synovial tissue of patients with known RA undergoing joint replacement surgery. The cells were pretreated with different concentrations of JAKi or vehicle control and then stimulated with IL1-b (10 or 20 ng/ ml) or Oncostatin M (OSM, 100 ng/ml). After the indicated time (17-24 hour), the supernatants were collected and the concentrations of IL-6 were measured by ELISA. An assay combining the measurement of cell viability, cytotoxicity and apoptosis was performed to exclude effects of JAKi caused by cell toxicity. Results In a pretest-setting, RA-FLS were pretreated with JAKi for 2 hour with concentrations of 1 mM and 10 mM and then stimulated with IL1-b (20 ng/ml) for 18 hour. At the concentration of 10 mM, Peficitinib, Filgotinib and Upadacitinib reduced the IL-6 release by RA-FLS, whereas Tofacitinib and Baricitinib did not change the IL-6-levels. Tofacitinib and Baricitinib at 1 and 5 mM only reduced the cytokine release if the IL-6 pathway was activated selectively with OSM (n=3). In further analyses, RA-FLS were again pretreated with Filgotinib and Peficitinib for 2 hour with clinically relevant concentrations (range between 0.01 mM and 5 mM) and then stimulated with IL1-b (10 ng/ml) for 17 hour. At the concentration of 5 mM, Peficitinib caused a reduction of IL-6 levels of 66% compared to control with IL1-b (p<0.01, n=5). However, a reduction of only 24% (p=0.12, n=5) could be observed at 1 mM. Filgotinib did not decrease IL-6 levels. Peficitinib did not change the viability, cytotoxicity or apoptosis (n=2), confirming that the observed effects were JAKi dependent. Conclusions Peficitinib reduced the inflammatory response of RA-FLS after activation with IL1-b and appeared to be superior to Tofacitinib and Baricitinib in targeting RA-FLS. The lack of effect of Tofacitinib and Baricitinib on RA-FLS activated by IL1-b could explain the treatment failure in some patients. 
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